Unveiling 5 Analyst Insights On Editas Medicine
Unveiling 5 Analyst Insights On Editas Medicine
揭示editas medicine的5个分析师见解
Throughout the last three months, 5 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish.
在过去的三个月中，有5位分析师对纳斯达克：EDIT的Editas Medicine进行了评估，提出了看好到看淡的不同观点。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
以下表格总结了分析师们最近的评级，揭示了过去30天内情绪的变化并将其与前几个月进行了比较。
In the assessment of 12-month price targets, analysts unveil insights for Editas Medicine, presenting an average target of $10.0, a high estimate of $15.00, and a low estimate of $7.00. This current average represents a 25.93% decrease from the previous average price target of $13.50.
在12个月的价格目标评估中，分析师揭示了Editas Medicine的见解，给出了一个平均目标价10.0美元，高估值为15.00美元，低估值为7.00美元。这个当前的平均值比之前的平均价格目标13.50美元下降了25.93%。
Interpreting Analyst Ratings: A Closer Look
解读分析师评级：更深入的了解
The analysis of recent analyst actions sheds light...
对最近的分析师行...
登录免费看全文
登录/注册